Original Tirzepatide: Discovery & Research History
Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) — how it was originally developed, and what it has been studied for since.
How Tirzepatide Was Discovered
Tirzepatide's development followed the path laid down by GLP-1 receptor agonists like semaglutide, but set out to go further. Researchers at Eli Lilly worked from a unimolecular dual-agonist design concept: rather than combining two separate hormone-mimicking drugs, they engineered a single synthetic peptide capable of activating two different incretin receptors at once — the GLP-1 receptor that semaglutide already targeted, and the GIP receptor, a related but distinct incretin pathway.
The result, first described in the scientific literature around 2018, was a single fatty-acid-conjugated peptide that engages both receptors, with research suggesting it activates the GIP receptor even more strongly than the GLP-1 receptor. That balance is thought to contribute to tirzepatide's larger weight-loss effect and, in some studies, fewer gastrointestinal side effects relative to single-target GLP-1 agonists.
What Tirzepatide Has Been Studied For
Tirzepatide received FDA approval as Mounjaro in 2022 for type 2 diabetes, followed by approval as Zepbound in 2023 specifically for chronic weight management. The Phase 3 SURMOUNT-1 trial reported 16.0–22.5% mean weight loss over 72 weeks, and a later head-to-head trial found tirzepatide outperformed semaglutide directly.
- Dual incretin-receptor agonism research
- Comparative GLP-1/GIP mechanism studies
- Weight-management and metabolic research
Read our Weight Loss & Metabolic research overview →
Tirzepatide discovery & history questions
Does Tirzepatide's research history mean it's approved for a particular use?
No. This page describes how Tirzepatide was originally developed and what it has been studied for since — it is historical and educational context, not a claim about current regulatory approval, safety, or legal status anywhere. KYIN Peptides sells Tirzepatide strictly for laboratory research use.
What has Tirzepatide been studied for in research?
Tirzepatide is studied for dual GIP/GLP-1 receptor agonism in weight-management and metabolic research, and is FDA-approved as the pharmaceuticals Mounjaro and Zepbound.
Looking for Tirzepatide specs and pricing?
View purity, available sizes, and pricing on the product page.